Alcon launches new Systane PRO preservative-free in the US

News
Article

Systane PRO preservative-free is the longest lasting dry eye drop in the Systane portfolio, according to Alcon.

Alcon announces US launch of Systane PRO preservative free - Image credit: Adobe Stock / ©mputsylo

(Image credit: Adobe Stock / ©mputsylo)

Alcon has announced the US launch of Systane PRO preservative-free (PF), a fresh addition to the company’s longstanding Systane portfolio. According to Alcon, Systane PRO PF is the longest lasting eye drop in the Systane line. While the drop is not a long-term solution to dry eye disease (DED), its triple action, preservative-free formula temporarily relieves burning and irritation due to eye dryness.1

“We are proud to introduce SYSTANE PRO PF, the first and only multi-dose preservative-free triple action formula with hyaluronate, nano-sized lipids and HP-Guar that support the active ingredient giving patients long-lasting relieffrom the symptoms of dry eye,” Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety at Alcon, said in a press release. “This is another example of how Alcon is bringing innovation to the SYSTANE portfolio to address the needs of dry eye patients.”

Systane PRO preservative free launches in the US - Image courtesy of Alcon

(Image courtesy of Alcon)

DED remains one of the most common ocular surface disorders, with incidence rising due to compromised tear stability and moisture retention tied to increased digital device usage, aging, and environmental irritants. The triple action formulation of Systane PRO PF provides sustained hydration, restores tear film stability, and protects against additional irritation to give patients long-lasting relief from DED symptoms.

“As an eye care professional and global dry eye expert, I know that patients should benefit from the design of a triple action preservative-free formula that includes hyaluronate to address all types of dry eye,” Selina McGee, OD, FAAO, Founder and Chief Optometrist of Bespoke Vision in Edmond, Oklahoma, said in a press release. “SYSTANE PRO PF provides hydration and protection of the ocular surface and can also stabilize the lipid layer of the tear film to reduce evaporation and provide lasting dry eye relief for my patients.”

The launch will begin in the US in February and will extend to additional markets in 2026. Alcon will feature Systane PRO PF at SECO, which is happening February 26-March 2, 2025, in Atlanta, Georgia.

Reference
1. Alcon announces US launch of new SYSTANE PRO preservative-free, revolutionizing dry eye relief with its longest lasting formula yet. Alcon. Press release. Published February 24, 2025. Accessed February 24, 2025. https://www.alcon.com/media-release/alcon-announces-us-launch-new-systane-pro-preservative-free-revolutionizing-dry-eye/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.